|
|
|
| Analysis of oral hypoglycemic drugs used in Outpatient Department of Xianning Central Hospital from 2017 to 2019 |
| MAO Kang1 HU Ning2 ZENG Jin3▲ |
1.Department of Pharmacy, Xianning Central Hospital, Hubei Province, Xianning 437000, China;
2.Department of Oncology, Xianning Central Hospital, Hubei Province, Xianning 437000, China;
3.Department of Pharmacy, Liyuan Hospital of Tongji Medical College of Huazhong University of Science and Technology, Hubei Province, Wuhan 430077, China |
|
|
|
|
Abstract Objective To analyze the current situation of oral hypoglycemic drugs in Xianning Central Hospital from 2017 to 2019, so as to promote rational drug use.Methods The data of oral hypoglycemic drugs used in the Outpatient Department of Xianning Central Hospital from 2017 to 2019 were analyzed by retrospective method, including amount of medication, defined daily dose (DDD), defined daily dose system (DDDs), defined daily cost (DDC) and ranking ratio(B/A).Results From 2017 to 2019, the consumption sum of various oral hypoglycemic drugs was increased year by year, among which the top three sales amounts were α-Glucosidase Inhibitors, Glinides and Biguanides.The top three DDDs from 2017 to 2019 were Acarbose, Metformin (imported), Metformin (domestic) and Saxagliptin.From 2017 to 2019, DDC of all kinds of oral hypoglycemic drugs was ＜100.From 2017 to 2019, the B/A of most oral hypoglycemic drugs was in the range of 0.5-1.5, the smallest was Acarbose, and the largest was Metformin (imported).Conclusion From 2017 to 2019, the use of oral hypoglycemic drugs in the Outpatient Department of Xianning Central Hospital is basically reasonable and economical.
|
|
Received: 14 December 2020
|
|
|
|
| [1] |
中华医学会糖尿病学分会.中国2 型糖尿病防治指南（2017年版）[J].中华糖尿病杂志，2018，10（1）：4-67.
|
| [2] |
段凌志.医院门诊口服降糖药物的应用情况[J].中国药物经济学，2019，14（12）：20-24.
|
| [3] |
Hu C，Jia W.Diabetes in China：epidemiology and genetic risk factors and their clinical utility in personalized medication[J].Diabetes，2018，67（1）：3-11.
|
| [4] |
Sahay M，Kalra S，Badani R，et al.Diabetes and Anemia：International Diabetes Federation（IDF）-Southeast Asian Region（SEAR）position statement[J].Diabetes Metab Syndr，2017，11（2）：S685-S695.
|
| [5] |
陈新谦，金有豫，汤光.新编药物学[M].17 版.北京：人民卫生出版社，2003：609-617.
|
| [6] |
李飞，徐晴晴，赵晓燕，等.2014年4月至2017年3月解放军总医院门诊口服降糖药应用分析[J].中国医院用药评价与分析，2019，19（3）：348-352.
|
| [7] |
计晓军.2015—2017年中国科技大学第一附属医院门诊口服降糖药应用分析[J].中国医院用药评价与分析，2019，19（1）：78-80.
|
| [8] |
谢强明，黄渊秀，刘鲲，等.长沙市成人糖尿病治疗和控制现状及影响因素分析[J].中国慢性病预防与控制，2017，25（5）：325-328.
|
| [9] |
钟询龙，王若伦.2018年广州医科大学附属第二医院糖尿病患者降糖药物的使用情况分析[J].现代药物与临床，2019，34（12）：3733-3738.
|
| [10] |
钟丽颖，孙叶海，王聪，等.甘精胰岛素联用阿卡波糖治疗老年糖尿病患者的临床效果及安全性探讨[J].中国现代医生，2019，57（32）：26-28.
|
| [11] |
蔡俊，计成，朱巧玲，等.2016～2018年南京地区降糖药物使用情况分析[J].药物流行病学杂志，2020，29（6）：424-429.
|
| [12] |
何美艳，李远，邹丹婷，等.沙格列汀联合胰岛素治疗在2 型糖尿病中的应用效果[J].中国当代医药，2020，27（20）：73-75，79.
|
| [13] |
唐宗虎.2014～2016年我院糖尿病药物的用药分析[J].海峡药学，2018，30（7）：272-274.
|
| [14] |
刘向阳，曹宏伟，赖敬波，等.恩格列净联合二甲双胍治疗新诊断超重及肥胖2 型糖尿病的临床观察[J].解放军医药杂志，2020，32（9）：26-29.
|
| [15] |
李洁，陈诚，宋文荣.西格列汀联合二甲双胍治疗2 型糖尿病的疗效观察[J].中国医院用药评价与分析，2019，19（4）：441-442，444.
|
| [16] |
仇海燕，孔利萍，马丽珍.二甲双胍联合利拉鲁肽治疗肥胖2 型糖尿病的临床疗效及安全性评价[J].中国现代医生，2019，57（17）：98-101.
|
|
|
|
